If you are having problems viewing this page, load here

GXPNews.com - FDA News and Announcements - February 22 - February 26, 2010

The once a week newsletter reporting on what's new with the Food and Drug Administration (FDA)
Distributed by the leader in Federal Regulations,
GMP Publications & FDA.COM - Feedback:
GXPNews Editor

GMP Publications FDA CFR Handbooks FDA.COM Food and Drug Assistance for Industry and Consumers

Drug GMP Handbooks  |  Clinical Handbooks  |  Device Handbooks  |  Biological Handbooks
GLP Master Handbook -
Clinical Master Guide - Canadian GMPs - Pharmacovigilance Vol. 9a Electronic Systems

GMP Publications FDA Mini-Regulation Handbooks
Books>Pharma GMPsMedical DeviceClinicalFood-Diet-CosmeticBiologic-Cell-BloodLaboratoryPart 11EU-Can-Misc.
Business B2B for the Regulated Industry Sparta Systems Track Wise Interphex 2010

Stay up to date with the FDA CFR changes - Enter Email:     Archive

FDA Press Announcements | Stay current with the FDA Rule Updates | Pick up your free CFRs at Interphex!

Center for Drug Evaluation &
Research (CDER) News
Drug Approvals - Meetings - Links

Center for Biologics Evaluation
& Research (CBER)
Meetings - Links

Center for Device &
Radiological Health (CDRH)
Meetings - Links

Federal Register - Meetings, Notices, &  Rule Changes

CDER NEWS
February 26, 2010

February 25, 2010

February 24, 2010

February 23, 2010

February 22, 2010

Drug Approvals
February 25, 2010
  • Bystolic (nebivolol hydrochloride) Tablets, Forest Laboratories, Inc., Efficacy Supplement
  • Cayston (aztreonam) Inhalation Solution, Gilead Sciences, Inc., Approval
  • Cefoxitin and Dextrose in Duplex Container Injection, B. Braun Medical, Inc., Labeling Revision
  • Cyanokit (hydroxocobalamin) Injection, Merck Sante s.a.s., Labeling Revision
  • Dyazide (hydrochlorothiazide and triamterene) Capsules, GlaxoSmithKline, Labeling Revision
  • Finasteride Tablets, Accord Healthcare, Inc., Approval 
  • Forane (isoflurane) Inhalation Liquid, Baxter Healthcare Corporation, Labeling Revision
  • Imiquimod Cream, Nycomed, Inc., Approval
  • Intelence (etravirine) Tablets, Tibotec, Inc., Labeling Revision
  • Marcaine (bupivacaine hydrochloride) Injection, Hospira, Inc., Labeling Revision
  • Marcaine (bupivacaine hydrochloride) Injection, Hospira, Inc., Labeling Revision
  • Naratripta Tablets, Roxane Laboratories, Inc., Tentative Approval
  • Niaspan (niacin) Extended-Release Tablets, Abbott Laboratories, Labeling Revision
  • Norethindrone and Ethinyl Estradiol Tablets, Watson Laboratories, Inc., Approval
  • Polyethylene Glycol 3350 and Electrolytes Oral Solution, Paddock Laboratories, Approval
  • Rocaltrol (calcitriol) Capsules, Validus Pharmaceuticals, Labeling Revision
  • Septocaine (articaine hydrochloride and epinephrine) Injection, Deproco, Inc., Labeling Revision
  • Tamiflu (oseltamivir phosphate) Capsules, Hoffmann-La Roche, Inc., Labeling Revision and Efficacy Supplement
  • Tamiflu (oseltamivir phosphate) Oral Suspension, Hoffmann-La Roche, Inc., Labeling Revision and Efficacy Supplement
  • Tracleer (bosentan) Tablets, Actelion, Ltd., Labeling

February 24, 2010

  • Carbocaine (mepivacaine hydrochloride) Injection, Hospira, Inc., Labeling Revision
  • Desloratadine Tablets, Orchid Healthcare, Approval
  • Mirapex ER (pramipexole dihydrochloride) Extended-Release Tablets, Boehringer Ingelheim Pharmaceuticals, Inc., Approval
  • Naropin (ropivacaine hydrochloride monohydrate) Injection, APP Pharmaceuticals, Labeling Revision
  • Nesacaine (chloroprocaine hydrochloride) Injection, APP Pharmaceuticals, Labeling Revision 
  • Xylocaine (lidocaine hydrochloride) Injection, APP Pharmaceuticals, Labeling Revision
  • Xylocaine 4% Preservative Free (lidocaine hydrochloride) Injection, APP Pharmaceuticals, Labeling Revision

February 23, 2010

  • Alendronate Sodium Tablets, Cadista Pharmaceuticals Inc., Approval
  • Baclofen Tablets, Matrix Laboratories Ltd., Approval
  • Caduet (amlodipine besylate and atorvastatin calcium) Tablets, Pfizer, Inc., Labeling Revision 
  • Ciclopirox Topical Solution, VersaPharm Inc., Approval
  • Coartem (artemether and lumefantrine) Tablets, Novartis Pharmaceuticals Corp., Labeling Revision
  • Donepezil Hydrochloride Tablets, Torrent Pharmaceuticals Ltd., Tentative Approval
  • Metformin Hydrochloride Extended-Release Tablets, Torrent Pharmaceuticals Ltd., Approval 
CDER Meetings
CDER Links

Guidance

Approved Drugs

Approval Process

Electronic Submissions

Firm Registration Status

Good Manufacturing Practice Regulations

National Drug Code Directory

MedWatch: Adverse Event Reporting

Download Forms

Generic Drugs

Small Business

En Espaρol

CBER NEWS
CBER Meetings
CBER Links
About CBER 

CBER Vision & Mission 
Biologics Research, Regulatory Information, Safety & Availability, Guidances, Development & Approval, Enforcement & Compliance

News & Events (Biologics) 
What's New, Meetings & Workshops

CBER Reports 
CBER Annual Report, Performance, FDAMA, PDUFA, FDAAA, PREA

Biologics Regulated Products 
Allergenics, Blood & Blood Products, Cellular & Gene Therapy Products, Tissue & Tissue Products, Vaccines, Xenotransplantation

Contacts in the Center for Biologics Evaluation & Research (CBER) 
Consumer questions, manufacturer's assistance, media inquiries, technical questions, requesting speakers, establishment registration...

Jobs at the Center for Biologics Evaluation and Research (CBER) 

Frequently Asked Questions about the Center for Biologics Evaluation and Research (CBER) and the Products CBER Regulates 

Biologics Electronic Reading Room (eFOI) 
Documents frequently requested through the Freedom of Information Act.

 

CDRH NEWS

February 26, 2010

February 23, 2010

February 22, 2010

CDRH Meetings
CDRH Links
Guidance Documents (Medical Devices) 

How to Market Your Device 

Postmarket Requirements (Devices) 

Importing and Exporting Devices 

International Information (Devices) 

Device Classification 

Bioresearch Monitoring 

FDA eSubmitter 

CDRH Learn 

Weekly CFR Rule Changes - Monday - 558

Fri, February 26, 2010
RULES - NONE

 
NOTICES
Agency Information Collection Activities; Proposals, Submissions, and Approvals:
     Mental Models Study of Recruitment and Retention of Pregnant Women Into An Asthma Pregnancy Registry
     8957–8959 [2010–3912]   [TEXT]  [PDF]
     Reporting and Recordkeeping Requirements and Availability of Sample Electronic Products for Manufacturers and Distributors of Electronic Products
     8963–8966 [2010–4002]   [TEXT]  [PDF]
     Substances Prohibited From Use in Animal Food or Feed; Animal Proteins Prohibited in Ruminant Feed
     8959–8960 [2010–3911]   [TEXT]  [PDF]
     Third Party Disclosure and Recordkeeping Requirements for Reportable Food
     8960–8963 [2010–4003]   [TEXT]  [PDF]
    
Draft Guidance for Industry:
     Adaptive Design Clinical Trials for Drugs and Biologics; Availability
     8968–8970 [2010–3980]   [TEXT]  [PDF]

Guidance for Industry on Submission of Documentation:
    Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes
     8970–8971 [2010–3978]   [TEXT]  [PDF]
 
Thurs, February 25, 2010
RULES - NONE

 
NOTICES - NONE

 
Wed, February 24, 2010
RULES - NONE

 
NOTICES
Meetings:
     Advisory Committee for Pharmaceutical Science and Clinical Pharmacology
     8368–8369 [2010–3594]   [TEXT]  [PDF]
     Device Improvements to Reduce Unnecessary Radiation Exposure from Medical Imaging; Request for Comments
     8375–8377 [2010–3674]   [TEXT]  [PDF]
     Pulmonary-Allergy Drugs Advisory Committee
     8377 [2010–3595]   [TEXT]  [PDF]
 
Tue, February 23, 2010
RULES - NONE

 
NOTICES
Debarment Orders:
     Patrick J. Lais
     8081–8082 [2010–3552]   [TEXT]  [PDF]

Preventive Controls for Fresh Produce; Request for Comments
8086–8087 [2010–3409]   [TEXT]  [PDF]
 
Mon, February 22, 2010
RULES
New Animal Drugs for Use in Animal Feeds:
     Bacitracin Zinc; Nicarbazin
     7555 [2010–3328]   [TEXT]  [PDF]
 
NOTICES
Agency Information Collection Activities; Proposals, Submissions, and Approvals:
     Experimental Study of Graphic Cigarette Warning Labels
     7604–7606 [2010–3320]   [TEXT]  [PDF]

Request for Environmental Impact Data and Information:
     Safety and Efficacy Review for Additional Ingredients in Over-the-Counter Drug Products for Human Use
     7606–7608 [2010–3319]   [TEXT]  [PDF]
 
 
 
 

GXP Academy  |  Conferences  |  Discussions  |  FDA.COM Job Board  |  On-Demand Printing - Custom CRFs

New!  -  GLP Master Handbook - 2009 Canadian GMPs - Eudralex Pharmacovigilance Volume 9a Electronic Systems Master Handbook |  Fax Form

The e-Newsletter of
What's New with CDER, CDRH & CBER
Distributed by the worlds leader in Federal Regulations,
GMP Publications, Inc.  & FDA.COM
Tel: 866-GXPNews (or 856-810-7331)  Fax: 856-810-7339
http://www.gmppublications.com / http://www.fda.com    John Cuspilich, Sr. Editor, GXPNews

If you would like to advertise in this eNewsletter, call 856-810-1825